Blueprint And Ardelyx Join List Of Biotechs Selling Royalties To Raise Funds

Amid Market Doldrums

 
• By Ayisha Sharma
  
Biotech Firms Are Selling Future Royalties Amid The Cash Crunch • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business